{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreifgkuhl6th2gvpmkuvijamwvuobrlx6xuyxki6yolstqk4ffvlyl4",
    "uri": "at://did:plc:ox2kiwcr2xmn32p25g472pp7/app.bsky.feed.post/3mogwxuukg4d2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreiavsgfmlqrcslxgv6zib2ve3xzdlyo5cjtrzz3guxg7ojhxd6bt4a"
    },
    "mimeType": "image/webp",
    "size": 136770
  },
  "path": "/releases/2026/06/260615033838.htm",
  "publishedAt": "2026-06-16T09:10:09.000Z",
  "site": "https://www.sciencedaily.com",
  "textContent": "Many people prescribed GLP-1 drugs for type 2 diabetes (such as Victoza, Ozempic, or tirzepatide) stop taking them, but a surprising number later return to treatment. Researchers found that newer medications appear to keep patients on therapy longer, while side effects remain a major reason for discontinuation.",
  "title": "Most people who stop GLP-1 drugs like Ozempic eventually return"
}